RevealAI-Lung
RevealDx
Information source:
Vendor
Last updated: November 7, 2024 |
General Information
General | |
---|---|
Product name | RevealAI-Lung |
Company | RevealDx |
Subspeciality | Chest |
Modality | CT |
Disease targeted | Lung cancer |
Key-features | Nodule malignancy similarity score |
Suggested use | During: interactive decision support (shows abnormalities/results only on demand) |
Technical Specifications
Data characteristics | |
---|---|
Population | Incidental nodules and those found during screening |
Input | CT, 3D, contrast, non-contrast |
Input format | DICOM |
Output | Malignancy Similarity Index (mSI) |
Output format | To be determined |
Technology | |
Integration | Integration in standard reading environment (PACS) |
Deployment | Locally on dedicated hardware, Cloud-based |
Trigger for analysis | On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | < 3 sec |
Regulatory
Certification | |
---|---|
CE |
Certified,
Class IIa
, MDD
|
FDA | No or not yet |
Intended Use Statements | |
Intended use (according to CE) | Design and manufacture of software intended as a decision aid for analysis of computed tomography (CT) scans of the lung for cancer diagnosis. |
Market
Market presence | |
---|---|
On market since | 05-2021 |
Distribution channels | contextflow, Amplify SDK, Riverain Technologies |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | 2 |
Pricing | |
Pricing model | Pay-per-use, Subscription |
Based on | Number of analyses |
Evidence
Evidence | |
---|---|
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance | |
Other relevant papers |